Arrowhead Pharmaceuticals Inc.
ARWR
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.2B
Close$
$-3.88
104.5% downside
Current Fair Value
104.5% downsideOvervalued by 104.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $12.20 Billion |
|---|---|
| Enterprise Value | $13.11 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 1.29 |
| Outstanding Shares | 143,378,000 |
Return
| Return on Equity | -68.73% |
|---|---|
| Return on Assets | -15.15% |
| Return on Invested Capital | -10.77% |
Valuation & Multiples
| P/E Ratio | -38.68 |
|---|---|
| PEG | -356.01 |
| Price to Sales | 21.4 |
| Price to Book Ratio | 28.53 |
| Enterprise Value to Revenue | 19.58 |
| Enterprise Value to EBIT | -66.54 |
| Enterprise Value to Net Income | -41 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 2.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-1.19
Average shareholder expectationRevenue Estimate
$47.89 M
Average shareholder expectationNext Earnings Call
Expected Date
November 24, 2026
EPS Estimate
$-1.52
Average shareholder expectationRevenue Estimate
$71.76 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.6674▲ 13.44% |
|---|---|
| Total Calls | 43,600▼ 97.28% |
| Total Puts | 29,100▼ 96.59% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 20.78%▼ 65.47% |
|---|---|
| Total Invested | $2.41B▼ 68.16% |
| Investors Holding | 224▼ 235.00% |
ESG Score
No data
About Arrowhead Pharmaceuticals Inc.
CEO: Christopher Anzalone